Background: Immunomodulatory drugs have been used in patients with severe COVID-19. The objective of this study was to evaluate the effects of two different strategies, based either on an interleukin-1 inhibitor, anakinra, or on a JAK inhibitor, such as baricitinib, on the survival of patients hospitalized with COVID-19 pneumonia.
Methods: Individuals admitted to two hospitals because of COVID-19 were included if they fulfilled the clinical, radiological, and laboratory criteria for moderate-to-severe disease. Patients were classified according to the first immunomodulatory drug prescribed: anakinra or baricitinib. All subjects were concomitantly treated with corticosteroids, in addition to standard care. The main outcomes were the need for invasive mechanical ventilation (IMV) and in-hospital death. Statistical analysis included propensity score matching and Cox regression model.
Results: The study subjects included 125 and 217 individuals in the anakinra and baricitinib groups, respectively. IMV was required in 13 (10.4%) and 10 (4.6%) patients, respectively ( = 0.039). During this period, 22 (17.6%) and 36 (16.6%) individuals died in both groups ( = 0.811). Older age, low functional status, high comorbidity, need for IMV, elevated lactate dehydrogenase, and use of a high flow of oxygen at initially were found to be associated with worse clinical outcomes. No differences according to the immunomodulatory therapy used were observed. For most of the deceased individuals, early interruption of anakinra or baricitinib had occurred at the time of their admission to the intensive care unit.
Conclusions: Similar mortality is observed in patients treated with anakinra or baricitinib plus corticosteroids.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432474 | PMC |
| http://dx.doi.org/10.3390/jcm10174019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review on the current approaches and perspectives of Covid-19 treatment.
Pol Merkur Lekarski
July 2024
FACULTY OF SCIENCE AND TECHNOLOGY, JAN DLUGOSZ UNIVERSITY IN CZESTOCHOWA, CZESTOCHOWA, POLAND.
At the beginning of 2020, the world was faced with the challenge of the coronavirus disease 2019 (COVID-19) pandemic announced by the WHO on March 11, caused by the betacoronavirus type 2 of the severe acute respiratory syndrome (SARS-CoV-2), which had profound health, sociological and even economic consequences. The quickly implemented and large-scale research resulted in the introduction of widely available vaccines that reduced the further development of the pandemic and antivirals against SARS-CoV-2. Currently, 11 antiviral drugs (Tixagevimab/Cilgavimab, Regdanvimab, Casirivimab/Imdevimab, Sotrovimab, Nirmatrelvir/Ritonavir, Remdesivir, Molnupiravir, Baricitinib, Anakinra, Tocilizumab, Vilobelimab) have been approved or conditionally approved by the European Medicines Agency and/or by the Food and Drug Administration and are available on the pharmaceutical market.
View Article and Find Full Text PDFComparative efficacy and safety of different drugs in patients with systemic juvenile idiopathic arthritis: A systematic review and network meta-analysis.
Medicine (Baltimore)
May 2024
Department of Pharmacy, Huaihe Hospital of Henan University, Kaifeng, Henan, China.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of various biological agents for treating systemic juvenile idiopathic arthritis (JIA), comparing them to a placebo through a network meta-analysis.
- After analyzing data from 10 studies involving 898 participants, canakinumab was found to be statistically more effective than placebo, leading the efficacy rankings, followed by anakinra and adalimumab.
- Despite the variations in effectiveness, there were no significant differences in adverse events among the treatments, indicating that canakinumab is a suggested option for JIA management based on both efficacy and safety measures.
Drugs and natural products for the treatment of COVID-19 during 2020, the first year of the pandemic.
Bol Med Hosp Infant Mex
March 2024
Facultad de Ciencias, Universidad Nacional Autónoma de México.
This work aimed to show which treatments showed efficacy against coronavirus disease 2019 (COVID-19); therefore, the results of 37 clinical trials started in 2020 and completed in 2021 are reviewed and discussed here. These were selected from databases, excluding vaccines, computational studies, in silico, in vitro, and those with hyperimmune sera from recovered patients. We found 34 drugs, one vitamin, and one herbal remedy with pharmacological activity against symptomatic COVID-19.
View Article and Find Full Text PDFCombination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.
Int Immunopharmacol
March 2024
Department of Internal Medicine, Aksaray Training and Research Hospital, Aksaray, Turkey.
Introduction: In this study, we aimed to evaluate the safety and efficacy of combination treatment of high-dose intravenous anakinra and baricitinib in patients with critically ill COVID-19.
Material And Methods: This retrospective observational study was conducted in a tertiary center with diagnosis of COVID-19 patients.Study population consisted of patients with positive polymerase chain reaction and computer tomography findings compatible with COVID-19 as well as critical illness.
Adjunctive treatment in COVID-19 and sepsis-What did we learn?
Med Klin Intensivmed Notfmed
December 2023
Fourth Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Medical School, 1 Rimini Street, 124 62 Athens, Greece.
The introduction of anakinra, baricitinib and tocilizumab into the treatment armamentarium of severe coronavirus disease 2019 (COVID-19) reinforced the concept of immunotherapy for bacterial sepsis. The current review investigates how the example of COVID-19 may be extrapolated to sepsis using a three-step approach. In the first step, the clinical evidence on how the immunotherapy of COVID-19 assisted viral clearance is presented.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!